AUA 2025: Real-World Time-to-next-Treatment and Time-to-Castration-Resistance Among Patients with Metastatic Castration-Sensitive Prostate Cancer Using Androgen-Receptor Pathway Inhibitors with and Without Homologous Recombination Repair Alterations
AUA 2025, prostate cancer, metastatic castration-sensitive prostate cancer (mCSPC), androgen receptor pathway inhibitors (ARPIs), Homologous Recombination Repair (HRR), Homologous Recombination Repair Alterations, AMPLITUDE trial, TALAPRO-3 trial.